

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the present application.

***Listing of Claims:***

1. **(Currently Amended)** A method for increasing the bioavailability of ~~an~~ at least one orally administered pharmaceutically active compound, wherein said pharmaceutically active compound is selected from the group consisting of camptothecin and a cytostatic camptothecin derivative, said method comprising:

~~orally administering a bioenhancer comprising an inhibitor of BCRP and said pharmaceutically active compound, wherein said inhibitor and said pharmaceutically active compound~~ an effective bioenhancing amount of GF120918, wherein said GF120918 and said at least one pharmaceutically active compound are concomitantly administered.

2. **(Currently Amended)** Method according to claim 1, wherein ~~the inhibitor~~ said GF120918 is administered simultaneously with ~~the pharmaceutical compound~~ said camptothecin or said cytostatic camptothecin derivative.

3-10. **(Cancelled)**

11. **(Currently Amended)** Method according to claim 1, wherein ~~the bioenhancer~~ said GF120918 inhibits binding of ATP to a BCRP mediated and/or related drug transport protein.

12. **(Original)** Method according to claim 11, wherein the protein is BCRP.

13-14. **(Canceled)**

15. **(Currently Amended)** Method according to claim ~~13~~, 1, wherein ~~the pharmaceutically active compound is a~~ said GF120918 and said camptothecin derivative are concomitantly administered.

16. **(Currently Amended)** Method according to claim 15, wherein ~~the pharmaceutically active compound~~ said camptothecin derivative is selected from the group consisting of topotecan, GG211, DX8951f, BNP1350, 9-aminocamptothecin, 9-nitrocamptothecin, CPT11 and any metabolites thereof.

17. **(Original)** Method according to claim 16, wherein the metabolite is SN38.

18-21. **(Canceled)**

22. **(Currently Amended)** Pharmaceutical composition comprising GF120918 and at least one pharmaceutically active compound, wherein said pharmaceutically active compound is selected from the group consisting of a bioenhancer for increasing the bioavailability of a pharmaceutically active compound and said pharmaceutically active compound, said bioenhancer comprising an inhibitor of BCRP and said pharmaceutically active compound being selected from the group consisting of indolizino-quinoline derivatives, camptothecin and a camptothecin derivative derivatives, anthraquinone derivatives and quinazoline derivatives.

23-29. **(Canceled).**

30. **(Previously Presented)** A pharmaceutical composition, comprising:  
an effective amount of topotecan; and  
an effective amount of GF120918 to increase the bioavailability of said topotecan.

31. **(Previously Presented)** The pharmaceutical composition of claim 30, further comprising a pharmaceutically acceptable carrier suitable for oral administration.

32. **(Currently Amended)** A method for increasing the bioavailability of at least one orally administered pharmaceutically active compound, wherein said pharmaceutically active compound is selected from the group consisting of camptothecin and a camptothecin ~~camptothecin or a cytostatic camptothecin~~ derivative, comprising:

orally administering an effective bioenhancing amount of GF120918, wherein said GF120918 and said at least one pharmaceutically active compound ~~camptothecin or said cytostatic camptothecin derivative~~ are both present at overlapping periods of time.

33. **(Currently Amended)** The method according to claim 32, wherein the GF120918 is administered simultaneously with the ~~camptothecin~~ camptothecin or cytostatic ~~camptothecin~~ camptothecin derivative.

34. **(Currently Amended)** The method according to claim 32, wherein said ~~camptothecin~~ camptothecin or cytostatic ~~camptothecin~~ camptothecin derivative is topotecan.